Highly prevalent TERT promoter mutations in aggressive thyroid cancers

Endocrine-Related Cancer

Volumn 20, Issue 4, 2013, Pages 603-610

  Liu, Xiaoli ^a   Bishop, Justin ^a   Shan, Yuan ^b   Pai, Sara ^a   Liu, Dingxie ^a   Murugan, Avaniyapuram Kannan ^a   Sun, Hui ^c   El Naggar, AdelK ^d   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c JILIN UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

BRAF V600e mutation; Telomerase reverse transcriptase; TERT promoter mutations; Thyroid cancers; Thyroid tumorigenesis

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE;

ANAPLASTIC THYROID CANCER; ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; POORLY DIFFERENTIATED THYROID CANCER; PROMOTER REGION; SEQUENCE ANALYSIS; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TRANSLATION INITIATION;

BRAF V600E MUTATION; TELOMERASE REVERSE TRANSCRIPTASE; TERT PROMOTER MUTATIONS; THYROID CANCERS; THYROID TUMORIGENESIS;

CELL LINE, TUMOR; HUMANS; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; TELOMERASE; THYROID NEOPLASMS;

EID: 84882805198     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0210     Document Type: Article

References (25)

1. Capezzone M, Marchisotta S, Cantara S & Pacini F 2009 Telomeres and thyroid cancer. Current Genomics 10 526-533. (doi:10.2174/138920209789503897)
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417 949-954. (doi:10.1038/nature00766)
3. DeLellis RA, Lloyd R, Heitz PU, Eng C (Eds) 2004 WHO Classification of Tumors, Pathology and Genetics-Tumors of Endocrine Organs. Lyon, France: IARC Press.
4. Ghossein RA, Leboeuf R, Patel KN, Rivera M, Katabi N, Carlson DL, Tallini G, Shaha A, Singh B & Tuttle RM 2007 Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 17 655-661. (doi:10.1089/thy.2007.0061)
5. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K et al. 2013 TERT promoter mutations in familial and sporadic melanoma. Science 339 959-961. (doi:10.1126/science.1230062)
6. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H et al. (eds) 2012 SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute (http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012).
7. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S et al. 2006 Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. International Journal of Cancer 119 2322-2329. (doi:10.1002/ijc.22110)
8. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L & Garraway LA 2013 Highly recurrent TERT promoter mutations in human melanoma. Science 339 957-959. (doi:10.1126/science.1229259)
9. Janknecht R, Ernst WH & Nordheim A 1995 SAP1a is a nuclear target of signaling cascades involving ERKs. Oncogene 10 1209-1216.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
11. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC et al. 2013 TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. PNAS 110 6021-6026. (doi:10.1073/pnas. 1303607110)
12. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A & Xing M 2013 Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 12 1637-1638. (doi:10.4161/cc.24662)
13. LiVolsi VA 2010 Papillary carcinoma tall cell variant (TCV): a review. Endocrine Pathology 21 12-15. (doi:10.1007/s12022-010-9106-y)
14. Mocellin S, Pooley KA & Nitti D 2013 Telomerase and the search for the end of cancer. Trends in Molecular Medicine 19 125-133. (doi:10.1016/j. molmed.2012.11.006)
15. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS et al. 2012 American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22 1104-1139. (doi:10.1089/thy.2012.0302)
16. Smekalova EM, Shubernetskaya OS, Zvereva MI, Gromenko EV, Rubtsova MP & Dontsova OA 2012 Telomerase RNA biosynthesis and processing. Biochemistry 77 1120-1128. (doi:10.1134/S0006297912100045)
17. van Staveren WC, Solís DW, Delys L, Duprez L, Andry G, Franc B, Thomas G, Libert F, Dumont JE, Detours V et al. 2007 Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Research 67 8113-8120. (doi:10.1158/0008-5472.CAN-06-4026)
18. Strahl T, Gille H & Shaw PE 1996 Selective response of ternary complex factor Sap1a to different mitogen-activated protein kinase subgroups. PNAS 93 11563-11568. (doi:10.1073/pnas.93.21.11563)
19. Whitmarsh AJ, Shore P, Sharrocks AD & Davis RJ 1995 Integration of MAP kinase signal transduction pathways at the serum response element. Science 269 403-407. (doi:10.1126/science.7618106)
20. Xing M 2005a BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262. (doi:10.1677/erc.1.0978)
21. Xing M 2005b The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Clinical Endocrinology 63 263-266. (doi:10.1111/j.1365-2265.2005.02332.x)
22. Xing M 2013 Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews. Cancer 13 184-199. (doi:10.1038/nrc3431)
23. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 6373-6379. (doi:10.1210/jc.2005-0987)
24. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM et al. 2013a Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Journal of the American Medical Association 309 1493-1501. (doi:10.1001/jama.2013.3190)
25. Xing M, Haugen BR & Schlumberger M 2013b Promises in molecular-based management of differentiated thyroid cancer. Lancet 381 1058-1069. (doi:10.1016/S0140-6736(13)60109-9)